Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Choreo LLC

Choreo LLC boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 44.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,765 shares of the company’s stock after buying an additional 1,156 shares during the period. Choreo LLC’s holdings in Neurocrine Biosciences were worth $516,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Commerce Bank boosted its holdings in shares of Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after acquiring an additional 108 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in Neurocrine Biosciences by 2.7% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock valued at $496,000 after purchasing an additional 113 shares in the last quarter. Brooklyn Investment Group boosted its stake in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Tealwood Asset Management Inc. increased its position in shares of Neurocrine Biosciences by 1.0% during the 4th quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock valued at $1,626,000 after purchasing an additional 118 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Neurocrine Biosciences by 42.0% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after buying an additional 157 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Royal Bank of Canada dropped their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a report on Friday, February 7th. Piper Sandler reissued an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Finally, HC Wainwright decreased their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Stock Down 1.6 %

Shares of NASDAQ:NBIX opened at $116.85 on Wednesday. The firm has a fifty day moving average of $138.66 and a two-hundred day moving average of $131.23. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a market capitalization of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. This represents a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.